Novel therapeutic agent: Dopamine treatment of Myopia (DTOM)

Pre-clinical animal work has illustrated that an ophthalmic levodopa solution can prevent the onset and progression of experimental myopia in a dose-dependent manner, providing greater efficacy than atropine, the primary pharmacological treatment for human myopia. Importantly, no ocular side-effects were reported in preclinical animal models, or in a completed Phase Ib safety and tolerability trial (trial registration - ACTRN12620001259932) in 28 young males aged 18-30. Thus, topical levodopa treatment forms a novel, and potentially powerful avenue for myopia treatment. Therefore, this Phase II clinical trial will assess the safety and efficacy of levodopa as a myopia intervention in a paediatric population.